Free Trial
NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Price, News & Analysis

GlycoMimetics logo

About GlycoMimetics Stock (NASDAQ:GLYC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.16
$27.47
52-Week Range
N/A
Volume
1.05 million shs
Average Volume
63,887 shs
Market Capitalization
$10.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Moderate Buy

Company Overview

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GlycoMimetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

GLYC MarketRank™: 

GlycoMimetics scored higher than 36% of companies evaluated by MarketBeat, and ranked 781st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for GlycoMimetics are expected to remain at ($0.08) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about GlycoMimetics' valuation and earnings.
  • Percentage of Shares Shorted

    2.90% of the float of GlycoMimetics has been sold short.
  • Short Interest Ratio / Days to Cover

    GlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GlycoMimetics has recently increased by 1.79%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    GlycoMimetics does not currently pay a dividend.

  • Dividend Growth

    GlycoMimetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.90% of the float of GlycoMimetics has been sold short.
  • Short Interest Ratio / Days to Cover

    GlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GlycoMimetics has recently increased by 1.79%, indicating that investor sentiment is decreasing.
  • News Sentiment

    GlycoMimetics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for GlycoMimetics this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for GLYC on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GlycoMimetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.70% of the stock of GlycoMimetics is held by insiders.

  • Percentage Held by Institutions

    75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GlycoMimetics' insider trading history.
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

Crescent Biopharma Inc.
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
See More Headlines

GLYC Stock Analysis - Frequently Asked Questions

GlycoMimetics, Inc. (NASDAQ:GLYC) released its quarterly earnings data on Wednesday, May, 14th. The biotechnology company reported ($4.00) EPS for the quarter, beating the consensus estimate of ($5.00) by $1.00.

Shares of GlycoMimetics reverse split on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

GlycoMimetics' top institutional shareholders include Wellington Management Group LLP (2.12%) and Jefferies Financial Group Inc. (0.91%). Insiders that own company stock include Public Equities LP Invus, Edwin Rock, Bruce S Johnson and Brian M Hahn.
View institutional ownership trends
.

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Bristol Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
5/14/2025
Today
6/28/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLYC
Employees
50
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.88 million
Pretax Margin
-397,340.00%

Debt

Sales & Book Value

Annual Sales
$10 thousand
Price / Cash Flow
N/A
Book Value
$0.08 per share
Price / Book
N/A

Miscellaneous

Free Float
58,901,000
Market Cap
$10.00 million
Optionable
Optionable
Beta
1.62

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:GLYC) was last updated on 6/29/2025 by MarketBeat.com Staff
From Our Partners